Development of a Noninvasive Method of Evaluation of Pulmonary Inflammation in the Condensates of Exhaled Air

NCT00356629 | Terminated

• 1 other identifier: AOHP06-PD Air Exhalé
• Study Type: observational
• Target: 100
• Locations: 1 country
• Sites: 1

Brief Summary

The aim of the study is identify biological parameters reflecting proteolytic activity in the exhaled condenstaes which might be useful to follow up pulmonary inflammation in various conditions including cystic fibrosis, COPD, asthma, tobacco exposure. Three proteases will be analyzed, i.e. elastase, proteinase 3 and cathepsin G. Results in the condensates will be compared to those obtained in sputum.

Conditions

Bronchopulmonary Ignition; Condensate of Exhaled Air; Mucoviscidosis; Asthma

Keywords

bronchopulmonary ignition; condensate of exhaled air; Mucoviscidosis; Asthma

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

ubjects suffering from CF, COPD, asthma and tobacco exposure

You may qualify if:

• Subjects suffering from CF, COPD, asthma and tobacco exposure (groups 1 to 4) and controls (group 5)
• aged more or equal to 18
• stable disease
• able to perform PFTs
• informed consent signed
• affiliated to french social insurance

You may not qualify if:

• acute exacerbation of the disease during the last 2 weeks
• IV or oral steroids or antibiotics during the last 2 weeks
• hospitalization during the last 2 weeks
• colonization by S aureus methicillin resistant and/or Burkholderia cepacia

Sponsors & Collaborators

• University Hospital, Tours: lead

Study Sites (1)

Service de Pneumologie et EFR CHRU Tours

Tours, 37044, France

Location

Related Publications (2)

• Attucci S, Gauthier A, Korkmaz B, Delepine P, Martino MF, Saudubray F, Diot P, Gauthier F. EPI-hNE4, a proteolysis-resistant inhibitor of human neutrophil elastase and potential anti-inflammatory drug for treating cystic fibrosis. J Pharmacol Exp Ther. 2006 Aug;318(2):803-9. doi: 10.1124/jpet.106.103440. Epub 2006 Apr 20.

  PMID: 16627747 BACKGROUND

• Grimbert D, Vecellio L, Delepine P, Attucci S, Boissinot E, Poncin A, Gauthier F, Valat C, Saudubray F, Antonioz P, Diot P. Characteristics of EPI-hNE4 aerosol: a new elastase inhibitor for treatment of cystic fibrosis. J Aerosol Med. 2003 Summer;16(2):121-9. doi: 10.1089/089426803321919889.

  PMID: 12823906 BACKGROUND

Related Links

• Related Info

MeSH Terms

Conditions

Cystic Fibrosis; Asthma

Condition Hierarchy (Ancestors)

Pancreatic Diseases; Digestive System Diseases; Lung Diseases; Respiratory Tract Diseases; Genetic Diseases, Inborn; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Infant, Newborn, Diseases; Bronchial Diseases; Lung Diseases, Obstructive; Respiratory Hypersensitivity; Hypersensitivity, Immediate; Hypersensitivity; Immune System Diseases

Study Officials

• DIOT Patrice, Pr

  service de Pneumologie et EFR CHRU Tours

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER

Study Record Dates

• First Submitted: July 25, 2006
• First Posted: July 26, 2006
• Study Start: July 1, 2006
• Study Completion: July 1, 2008
• Last Updated: November 14, 2008

Record last verified: 2008-11

Locations

FR (1)